AdAlta Raises A$2.5M to Advance CAR-T Therapy BZDS1901 with FDA and Manufacturing Milestones

Placement to Fuel Regulatory and Manufacturing Progress

AdAlta Limited (ASX:1AD) has raised A$2.5 million through a private placement priced at 0.4 cents per share, accompanied by attaching options exercisable at 1 cent each. This capital injection aims to propel its pioneering CAR-T therapy BZDS1901 towards key regulatory milestones with the US Food and Drug Administration (FDA) and to establish a robust manufacturing base in Australia. The placement underscores investor confidence following encouraging clinical data showing multiple advanced mesothelioma patients responding to treatment, including cases of complete tumour clearance.

CEO Tim Oldham highlighted the significance of the funding in advancing both manufacturing reliability and regulatory engagement, noting a recent technology transfer agreement with Cell Therapies Pty Ltd to localise production. This move addresses a critical hurdle for CAR-T therapies, where scalable and consistent manufacturing is essential for commercial viability.

Clinical Data Highlights Uncommon Complete Responses

BZDS1901 has demonstrated rare clinical outcomes in a notoriously difficult-to-treat cancer. Early Chinese trials reported two complete tumour clearances in patients with advanced mesothelioma who had previously failed chemotherapy and immunotherapy. One patient remains alive 22 months post-treatment with no tumour recurrence, an exceptional result in this patient population. These findings reinforce the potential of BZDS1901 as a single-dose living drug with durable effects, leveraging CAR-T technology to arm immune cells against solid tumours.

Such outcomes have attracted sophisticated investors, fueling demand for the placement. The therapy’s unique approach includes secreting its own immune checkpoint inhibitor, a strategy designed to overcome tumour immune suppression, and a manufacturing process that avoids expensive viral vectors, delivering a product in under two days.

Strategic Manufacturing Shift to Australia

AdAlta’s decision to transfer manufacturing to Australia is a strategic response to evolving geopolitical and regulatory challenges. The company’s first Work Order with Cell Therapies Pty Ltd initiates this transition, which is expected to enhance manufacturing scalability and quality assurance. This local manufacturing footprint is increasingly valuable given recent US regulatory restrictions on clinical data from China and other countries considered hostile, which could limit the use of foreign-generated data in FDA submissions.

This Australian manufacturing move follows the company’s recent signing of a manufacturing transfer agreement and aligns with its broader “East to West” strategy that integrates Asian development efficiency with Western regulatory standards. The shift also positions AdAlta to navigate tighter US FDA scrutiny and capitalize on expedited approval pathways under consideration.

Geopolitical Factors Elevate Platform Value

AdAlta’s “East to West” platform, operated through its subsidiary AdCella, is gaining prominence amid tightening US policies on biotech R&D involving China and other countries. Since April 2026, a US House committee has proposed barring the FDA from accepting clinical data generated in China, Russia, Iran, or North Korea for investigational new drug applications. This development enhances the strategic importance of Australian-generated clinical data and manufacturing capabilities.

Moreover, the FDA’s 2025 halt on clinical trials involving the export of American citizens’ cells to foreign labs in hostile countries further restricts CAR-T manufacturing in China, underscoring the commercial advantage of AdAlta’s Australian manufacturing site. This geopolitical backdrop could accelerate the company’s ability to attract global partnerships and regulatory approvals.

Placement Terms and Shareholder Approval

The placement involves issuing approximately 625 million new shares and 208 million attaching options, exercisable at 1 cent until June 2028. Lead Manager 62 Capital Pty Ltd will receive a 6% fee in shares and options, plus additional lead manager options. About 106 million shares will be issued under existing placement capacity, with the remainder subject to shareholder approval at an Extraordinary General Meeting expected in early June.

Investors should note the placement price represents a 20% discount to the closing price on 29 April 2026 and a 14.9% discount to the 15-day VWAP prior to that date. The successful completion of the placement and shareholder approval will be key near-term catalysts.

AdAlta’s recent steps to secure Australian manufacturing for BZDS1901, alongside its clinical progress, have been documented in detail, including the manufacturing transfer signed with Cell Therapies and the rare tumour clearance in mesothelioma trial, both of which underpin the rationale for this capital raise.